Charles River Laboratories operates across three primary business segments: Discovery and Safety Assessment (DSA), Research Models and Services (RMS), and Manufacturing Solutions. The DSA segment, which generates the majority of the company's revenue, offers comprehensive services spanning from target identification through non-clinical drug development and toxicology. The RMS segment provides high-quality research animal models and associated services, while the Manufacturing Solutions segment focuses on microbial solutions, biologics testing, and cell and gene therapy contract manufacturing. With operations in over 20 countries, the company supports a vast majority of FDA-approved drugs. Recently, Charles River has increasingly invested in non-animal testing alternatives, known as New Approach Methods (NAMs), to align with evolving regulatory standards and client demands.
